Tissue factor-activated TEG, although typically insensitive to hypercoagulation compared to PT and aPTT, may be capturing the effects of vWF on platelet activation-stimulated cell-driven coagulation, which can be detected by whole blood-based, but not plasma-based, clot assays. The gene discussed is F3; the disease is thrombophilia.